Intravenous flumazenil following prolonged exposure to lormetazepam in humans: lack of precipitated withdrawal.
The capacity of flumazenil to reverse benzodiazepine agonist effects has been widely demonstrated. In contrast, the role of flumazenil in precipitating withdrawal symptoms is unclear in humans: the inability of RO 15-1788 to induce benzodiazepine withdrawal seems to be related to the duration of exposure to the GABAergic drugs. In the present experiment we evaluated the effects of intravenous flumazenil or placebo in 36 healthy volunteers pretreated with lormetazepam for 30 days (2 mg/day) and 18 lormetazepam-dependent subjects (6-8 mg/day). Measurements of a balance task, subject- and observer-rated symptoms showed a reversal of lormetazepam effects induced by flumazenil without any significant withdrawal symptoms. Slight anxiety, increase in heart rate and perspiration were observed in a few subjects. Independent of benzodiazepine doses, long-term treatment seems to be responsible for tolerance development with consistent changes in GABA-benzodiazepine receptor sensitivity. Flumazenil could be able to normalize benzodiazepine receptor sensitivity and exert its weak agonist activity.
Gerra
G
G
Centro Studi Farmacotossicodipendenze, SER.T., AUSL Parma, Italy.
Giucasto
G
G
Zaimovic
A
A
Fertonani
G
G
Chittolini
B
B
Avanzini
P
P
Caccavari
R
R
Delsignore
R
R
D000328:Adult; D014151:Anti-Anxiety Agents / Q000009:adverse effects*; D001569:Benzodiazepines; D004311:Double-Blind Method; D005442:Flumazenil / Q000008:administration & dosage*; D018757:GABA Modulators / Q000008:administration & dosage*; D006801:Humans; D007275:Injections, Intravenous; D008140:Lorazepam / Q000009:adverse effects / Q000031:analogs & derivatives*; D008297:Male; D013375:Substance Withdrawal Syndrome / Q000517:prevention & control*
D014151:Anti-Anxiety Agents; D018757:GABA Modulators; D001569:Benzodiazepines; D005442:Flumazenil; C023842:lormetazepam; D008140:Lorazepam